FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, announced the commercial availability of a new series of high-throughput, robotics-compatible reagent kits. These kits, developed in collaboration with Hamilton Robotics, are designed to automate and standardize the preparation of genetic material for sequencing, thereby enhancing the efficiency and consistency of large-scale, single-cell discovery studies.
The BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform make up the automated solution, which aims to replace the traditionally manual and labor-intensive process of constructing DNA libraries, an essential step in single-cell discovery studies. This collaboration is expected to minimize variability in results, reduce human error, and speed up the generation of material for genetic sequencing.
Steve Conly, worldwide president of BD Biosciences, emphasized the importance of standardizing the complex library preparation process to ensure reproducibility in scientific research, a fundamental aspect of advancing fields such as oncology and immunology. Matt Hamilton, CEO of Hamilton, echoed this sentiment by highlighting the role of their advanced automated solutions in maximizing the potential of single-cell multiomics research.
The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR automated liquid handling platform are now globally available for purchase. Laboratories and facilities that already have the NGS STAR installed can easily incorporate the new BD® assay into their existing workflows.
BD is recognized as one of the largest global medical technology companies and is committed to advancing health care by supporting health care providers with innovative technology, services, and solutions. The company's latest offering is part of its ongoing efforts to enhance clinical care and laboratory science.
This news is based on a press release statement from BD (Becton, Dickinson and Company).
In other recent news, Becton Dickinson (NYSE:BDX) (BD) has seen several significant developments. The global medical technology firm reported robust fiscal third-quarter results, with a 5.2% organic revenue growth and earnings per share (EPS) of $3.50, marking an 18% year-on-year increase. However, the company revised its organic growth guidance to between 5% and 5.25%, down from the previous range of 5.5% to 6.25%. Despite this, the EPS forecast for fiscal 2024 was raised to a range of $13.05 to $13.15.
BD also announced the settlement of a substantial portion of its hernia product litigation. The settlement, covered by BD's existing product litigation reserve, aims to reduce uncertainty for stakeholders involved in the settled cases. In terms of acquisitions, BD completed the purchase of Edwards Lifesciences (NYSE:EW)' Critical Care product group, now known as BD Advanced Patient Monitoring. This move aims to enhance BD's smart connected care solutions with advanced monitoring technologies and AI-driven clinical decision tools.
Citi upgraded BD from Neutral to Buy, setting a new price target of $275, while Jefferies adjusted its price target for BD to $305 from $315, maintaining a Buy rating. On the leadership front, Thomas Spoerel was appointed as Senior Vice President, CFO Regions, and Michael Feld assumed the role of executive vice president and president of BD's Life Sciences segment. These are the recent developments at Becton Dickinson.
InvestingPro Insights
BD's (NYSE: BDX) latest innovation in automation technology aligns well with its position as a prominent player in the Healthcare Equipment & Supplies industry, as highlighted by InvestingPro Tips. This move could potentially contribute to the company's expected net income growth this year, another insight provided by InvestingPro.
The company's financial health appears robust, with a market capitalization of $68.36 billion and revenue of $19.83 billion over the last twelve months as of Q3 2024, according to InvestingPro Data. BD's commitment to shareholder value is evident in its impressive dividend history, having raised its dividend for 53 consecutive years and maintained payments for 54 years, as noted in the InvestingPro Tips.
While BD trades at a high earnings multiple with a P/E ratio of 48.44, investors might find comfort in the company's consistent profitability and low price volatility. The stock's dividend yield of 1.61% and a dividend growth rate of 4.4% in the last twelve months further underscore BD's financial stability and shareholder-friendly policies.
For investors seeking a deeper understanding of BD's financial landscape, InvestingPro offers additional tips and insights. Currently, there are 8 more InvestingPro Tips available for BD, providing a comprehensive view of the company's performance and potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.